BrainsWay (NASDAQ:BWAY – Get Free Report) and Inspire Medical Systems (NYSE:INSP – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Profitability
This table compares BrainsWay and Inspire Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BrainsWay | -4.83% | -3.98% | -2.68% |
| Inspire Medical Systems | -2.38% | -2.82% | -2.40% |
Volatility and Risk
BrainsWay has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BrainsWay | $31.78 million | 3.50 | -$4.20 million | ($0.09) | -74.21 |
| Inspire Medical Systems | $624.80 million | 6.65 | -$21.15 million | ($0.55) | -254.27 |
BrainsWay has higher earnings, but lower revenue than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for BrainsWay and Inspire Medical Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BrainsWay | 0 | 1 | 2 | 0 | 2.67 |
| Inspire Medical Systems | 0 | 5 | 10 | 0 | 2.67 |
BrainsWay presently has a consensus target price of $13.00, indicating a potential upside of 103.76%. Inspire Medical Systems has a consensus target price of $235.29, indicating a potential upside of 68.11%. Given BrainsWay’s higher probable upside, equities research analysts clearly believe BrainsWay is more favorable than Inspire Medical Systems.
Insider & Institutional Ownership
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 19.0% of BrainsWay shares are held by insiders. Comparatively, 4.1% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Inspire Medical Systems beats BrainsWay on 8 of the 13 factors compared between the two stocks.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
About Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
